Transgene starts dosing in Phase Ib/II combination trial for HPV-positive cancers

Transgene has started dosing patients in a Phase Ib/II clinical trial of TG4001 in combination with avelumab to treat human papillomavirus type 16 positive (HPV-16+) recurrent or metastatic cancers.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news